Actavis announced that it will continue to distribute memantine HCI (Namenda) tablets due to a recent decision by a panel of the U.S. Court of Appeals for the Second Circuit.

The Court ruled to uphold a December 15, 2014 preliminary injunction requiring Actavis to continue distribution of Namenda 5mg and 10mg tablets. Forest Laboratories, a wholly owned subsidiary of Actavis, had previously announced plans to discontinue sales of the drug in the fall of 2014.

The reason for wanting to remove the drug from the market was allegedly to get patients to switch to Namenda XR, an extended-release version, before generics of immediate-release Namenda were to become available. It is now expected that will happen as soon as July.

Continue Reading

Namenda is an NMDA receptor antagonist approved for the treatment of moderate-to-severe dementia of the Alzheimer’s type. It is also available as Namenda oral solution.

Forest also recently launched Namzaric, a combination of Namenda XR and donepezil HCl (Aricept) for the treatment of moderate to severe Alzheimer’s.

For more information, go here.

This article originally appeared on MPR